- Legislation Introduced to Codify Stem Cell Rules
- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- The Top Science Progress Features of 2009
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
Brain Enhancement Makes its Way into the Workplace
From an online survey (subscription) of Nature readers comes data suggesting that a significant number of scientists and engineers use drugs for the non-medical purpose of increasing productivity and brain power. Wired Science reports that the survey questioned 1,427 readers who mostly worked in science, engineering, and education and focused on Ritalin, modafinil, and beta-blockers. These medications, when used off-label, can respectively increase levels of concentration, reduce the need for sleep, and lower anxiety. The Chronicle has the results:
- 20 percent of respondents report using medications to increase memory retention, concentration or focus.
- 60 percent of those who admitted non-medical use of cognitive-enhancing drugs used Ritalin.
- 44 percent of the admitting respondents used Provigil, known generically as modafinil.
- 15 percent admitted use beta-blockers.
- 9 out 10 respondents said they used the drugs to improve concentration and attention.
Science Progress advisory board member Martha Farah expressed concern about the ethical use of brain-enhancing drugs during a Seed Magazine-sponsored briefing on the Hill last month:
If higher productivity can come in a harmless pill, Farah wondered if workers might find themselves saying one day, “I want this job, but I don’t want to have to take a drug to get it.”
If Wired’s coverage is any indication, her concerns may already be manifest in some workplaces. In a recent edition of the magazine’s Mr. Know-It-All column, a reader asks the following question:
One of my coworkers, a rising star at the firm, is using unprescribed modafinil to work crazy hours. Our boss has started getting on my case for not being as productive. Should I tell him about my coworker’s pharmaceutical enhancement? Or should I start taking modafinil, too?
The question of what sort of social or governmental rules will govern such ethical choices about brain enhancement remains unanswered, but it’s obvious that deliberations have already begun.
Comments on this article
